Currently out of the existing stock ratings of Robert Driscoll, 220 are a BUY (88.35%), 28 are a HOLD (11.24%), 1 are a SELL (0.4%).

Robert Driscoll

Work Performance Price Targets & Ratings Chart

Analyst Robert Driscoll, currently employed at WEDBUSH, carries an average stock price target met ratio of 38.62% that have a potential upside of 54.79% achieved within 156 days.

Robert Driscoll’s has documented 486 price targets and ratings displayed on 38 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RVMD, Revolution Medicines at 28-Apr-2025.

Wall Street Analyst Robert Driscoll

Analyst best performing recommendations are on ABUS (ARBUTUS BIOPHARMA CORP).
The best stock recommendation documented was for ABUS (ARBUTUS BIOPHARMA CORP) at 10/9/2018. The price target of $5 was fulfilled within 1 day with a profit of $1 (16.67%) receiving and performance score of 166.67.

Average potential price target upside

of $43.75 (43.22%) on HARP (HARPOON THERAPEUTICS).
of $28.94 (70.12%) on IDRA (IDERA PHARMACEUTICALS).
of $14.42 (65.82%) on RCUS (ARCUS BIOSCIENCES).

ABUS Arbutus Biopharma Corp AKAO Achaogen ARVN Arvinas BDTX Black Diamond Therapeutics CDTX Cidara Therapeutics CTMX CytomX Therapeutics ELEV Elevation Oncology ETTX Entasis Therapeutics Holdings FPRX Five Prime Therapeutics HARP Harpoon Therapeutics IDRA Idera Pharmaceuticals IDYA Ideaya Biosciences IGMS IGM Biosciences KURA Kura Oncology RCUS Arcus Biosciences REPL Replimune Group SURF Surface Oncology FHTX Foghorn Therapeutics ACET Adicet Bio BCEL Atreca PRTK Paratek Pharmaceuticals ZNTL Zentalis Pharmaceuticals Llc CRVS Corvus Pharmaceuticals CMPX Compass Therapeutics CYT Cyteir Therapeutics DAWN Day One Biopharmaceuticals IMGO Imago Biosciences GERN Geron JANX Janux Therapeutics NBRV Nabriva Therapeutics AG ALPN Alpine Immune Sciences OMGA Omega Therapeutics TNGX Tango Therapeutics TYRA Tyra Biosciences APRE Aprea Therapeutics CGEM Cullinan Oncology LLC GLUE Monte Rosa Therapeutics RVMD Revolution Medicines

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Keay Nakae (CHARDAN CAPITAL)